The potential economic value of a human norovirus vaccine for the United States.

TitleThe potential economic value of a human norovirus vaccine for the United States.
Publication TypeJournal Article
Year of Publication2012
AuthorsBartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY
JournalVaccine
Volume30
Issue49
Pagination7097-104
Date Published2012 Nov 19
ISSN1873-2518
KeywordsAdolescent, Adult, Aged, Aged, 80 and over, Caliciviridae Infections, Child, Child, Preschool, Computer Simulation, Cost-Benefit Analysis, Female, Gastroenteritis, Humans, Infant, Infant, Newborn, Male, Middle Aged, Norovirus, United States, Viral Vaccines, Young Adult
Abstract

Vaccines against human norovirus are currently under development. We developed a simulation model to determine their potential economic value. Vaccination prevented 100-6125 norovirus gastroenteritis cases per 10,000 vaccinees. Low vaccine cost (≤$50) garnered cost-savings and a more expensive vaccine led to costs per case averted comparable to other vaccines. In the US, vaccination could avert approximately 1.0-2.2 million cases (efficacy 50%, 12 month duration), costing an additional $400 million to $1.0 billion, but could save ≤$2.1 billion (48 month duration). Human norovirus vaccination can offer economic value while averting clinical outcomes, depending on price, efficacy, and protection duration.

DOI10.1016/j.vaccine.2012.09.040
Alternate JournalVaccine
PubMed ID23026689
PubMed Central IDPMC3517973
Grant List1U54GM088491-0109 / GM / NIGMS NIH HHS / United States
U54 GM088491 / GM / NIGMS NIH HHS / United States
Publication Categories: